ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 571,57
0,91%
Dow Jones
38 778,10
0,49%
DAX
18 068,21
0,26%
Brent Oil
83,585
-0,38%
Bitcoin
65 515,70
-1,46%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Harrow Inc (HROW)

  7. Harrow Inc (HROW) Actualités

HROW

Harrow (HROW)

Harrow Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:HROW
DateHeureSourceTitreSymboleSociété
06/06/202414h00Business WireMelt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract SurgeryNASDAQ:HROWHarrow Inc
05/06/202413h00Business WireHarrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension StudyNASDAQ:HROWHarrow Inc
15/05/202413h00Business WireHarrow to Present at Two Investor Conferences in MayNASDAQ:HROWHarrow Inc
13/05/202422h01Business WireHarrow Announces First Quarter 2024 Financial ResultsNASDAQ:HROWHarrow Inc
13/05/202413h00Business WireHarrow Names Greg DiPasquale as Senior Vice President, Head of CommercialNASDAQ:HROWHarrow Inc
25/04/202413h00Business WireHarrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024NASDAQ:HROWHarrow Inc
02/04/202414h16Business WireMelt Pharmaceuticals Closes $24 Million Series B Preferred Stock FinancingNASDAQ:HROWHarrow Inc
20/03/202412h15IH Market NewsJPMorgan boosts dividends, Chipotle unveils 50:1 stock split, and Latest NewsNASDAQ:HROWHarrow Inc
19/03/202422h45Business WireHarrow Announces Fourth Quarter and Year-End 2023 Financial ResultsNASDAQ:HROWHarrow Inc
19/03/202412h27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:HROWHarrow Inc
06/03/202412h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HROWHarrow Inc
05/03/202413h00Business WireHarrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024NASDAQ:HROWHarrow Inc
15/02/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HROWHarrow Inc
15/02/202422h01Business WireHarrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical ProductsNASDAQ:HROWHarrow Inc
09/02/202422h05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:HROWHarrow Inc
29/01/202421h26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:HROWHarrow Inc
29/01/202413h00Business WireHarrow Announces New Appointments to its Board of DirectorsNASDAQ:HROWHarrow Inc
11/01/202413h00Business WireHarrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye DiseaseNASDAQ:HROWHarrow Inc
03/01/202413h15Business WireMelt Pharmaceuticals Provides Corporate UpdateNASDAQ:HROWHarrow Inc
03/01/202413h00Business WireHarrow Partners with Leading Healthcare Market Access Technology PlatformsNASDAQ:HROWHarrow Inc
29/11/202313h00Business WireHarrow Completes Transfer of the TRIESENCE® New Drug ApplicationNASDAQ:HROWHarrow Inc
20/11/202313h00Business WireHarrow to Present at Two Investor Conferences in NovemberNASDAQ:HROWHarrow Inc
13/11/202322h38Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HROWHarrow Inc
13/11/202322h01Business WireHarrow Announces Third Quarter 2023 Financial ResultsNASDAQ:HROWHarrow Inc
30/10/202313h00Business WireHarrow Will Release Third Quarter 2023 Financial Results on November 13, 2023NASDAQ:HROWHarrow Inc
24/10/202313h00Business WireHarrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.NASDAQ:HROWHarrow Inc
29/09/202314h00Business WireHarrow Health, Inc. Changes Corporate Name to Harrow, Inc.NASDAQ:HROWHarrow Inc
26/09/202314h00Business WireMelt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural SedationNASDAQ:HROWHarrow Inc
09/08/202322h01Business WireHarrow Announces Second Quarter 2023 Financial ResultsNASDAQ:HROWHarrow Inc
31/07/202313h00Business WireHarrow Launches VIGAMOX® in the U.S.NASDAQ:HROWHarrow Inc
 Showing the most relevant articles for your search:NASDAQ:HROW

Dernières Valeurs Consultées

EU
AF
Air FranceKLM
EU
BN
Danone
EU
BEL20
Bel 20
EU
CAP
Capgemini
EU
RNO
Renault
EU
RI
Pernod Ricard
EU
CS
Axa
EU
PX4
SBF 120
NASDAQ
GOOGL
Alphabet
FTSE
UKX
FTSE 100
EU
HO
Thales
EU
ACA
Credit Agricole
EU
PX1
CAC 40
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés